Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US5843398

Title:Radioimmunotherapy of lymphoma using anti-CD20 antibodies
Inventors:Kaminski, Mark S.; Ann Arbor, MI, USA
Butchko, Gregory M.; Miami Lakes, FL, USA
Glenn, Stephan D.; Davis, FL, USA
Wahl, Richard L.; Ann Arbor, MI, USA
Summary:Described herein is an immunotherapeutic method of treating B-cell lymphoma. The invention relates to the administration of a B cell-specific antibody which binds to CD20 antigens on lymphoma cells, in amounts determined by prior clearance rate studies. Further described are methods by which the patient receives both unlabeled antibodies and antibodies labeled with a radioisotope. Claims of the invention include advantages in tumor response which can be obtained in a radiometric dosage range that does not require hematopoietic stem cell replacement as an adjunct therapy.
Abstract:Methods for the treatment of lymphoma by administration of a B cell-specific antibody are described. The invention encompasses providing to a patient both unlabeled antibodies and antibodies labeled with a radioisotope. A principal advantage of the method is that tumor responses can be obtained in a radiometric dose range that does not require hematopoietic stem cell replacement as an adjunct therapy.
US Patent Website:Click Here for Full Text of Patent
Title Number:US5843398
Application Number:US1996000639882
Date Filed:26/04/1996
Date Published:01/12/1998
Assignee:Coulter Pharmaceutical, Inc., Palo Alto, CA, USA Regents of the University of Michigan, Ann Arbor, MI, USA


 
Copyright © 2007 The Institute for Cellular Medicine  6/22/2021